11/5/2026

speaker
Daniel
Conference Call Operator

Welcome to the Iovance Biotherapeutics third quarter 2026 conference call. My name is Daniel, and I will be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session. Please note that this conference call is being recorded. I would now turn the call over to Jen Saunders, Senior Director, Investor Relations and Corporate Communications at Iovance. Jen, you may begin.

speaker
Jen Saunders
Senior Director, Investor Relations and Corporate Communications

Thank you, Daniel. Good morning and welcome to the Iovance webcast to discuss our third quarter 2026 financial results, business achievements, and corporate updates. This morning, we issued a press release that is available on our corporate website at Iovance.com. This conference call will include forward-looking statements regarding Iovance's goals, business focus, business plans and transactions, revenue and revenue guidance, commercial activities, clinical trials and results, regulatory approvals, submissions, feedback and guidance, Plans and Strategies, Research and Preclinical Activities, Potential Future Applications of Our Technologies, Manufacturing Capabilities, Hair Interactions, Licenses and Collaborations, Cash Position, and Future Updates. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond our control, including the risks and uncertainties described from time to time in our FCC filings. Our results may differ materially from those projected during today's call. We undertake no obligation to publicly update any forward-looking statements. I will now turn the call over to Dr. Fred Vogt, Interim CEO and President. Thank you, Jen. Good morning, everyone.

speaker
Dr. Fred Vogt
Interim CEO and President

Our third quarter delivered outstanding record-setting results for Iovance, with our highest ever revenue and margin and strong financial performance across the board. The total revenue of about $122 million surged 80% over the prior year. U.S. ampagni revenue increased 77% over the prior year and crossed $100 million in a single quarter for the first time. We also passed an important landmark this quarter, with more than 1,000 commercial anti-AV patients now in use in the US since launch. Based on this strong performance, we remain on track to achieve our full year revenue guidance of $410 to $420 million. Our authorized treatment center, or ATC network, continues to expand rapidly, and we fully expect to reach 110 or more authorized treatment centers by year end. Third quarter margin of about 60% also saw also set a new all-time high for the second consecutive quarter, and we expect it to expand further over time. Our cash runway is now expected to fund operations well into 2029. The strong performance reflects the financial health of iAdvance and the strong platform that we can build upon for upcoming launches. The third quarter and recent updates also reflect major progress across our TIL platform and pipeline programs. and Metastatic Non-Small Cell Lung Cancer, Lepalucil continues to demonstrate a potentially best-in-class clinical profile. Earlier this year, the FDA granted Fast-Track designation based on the strength of our data and the high unmet need. Last week, we reported positive updated results from our Registrational Lung 202 trial that included 69 patients with previously treated non-squamous Metastatic Non-Small Cell Lung Cancer. The objective response rate, or ORR, by RESIST-11 was 24.6%. consistent with our prior results in 39 patients. Durability, while still maturing, was also consistent with our prior results and has already greatly surpassed the current standard of care, docetaxel, which has a response rate of only 12.8%, short durability of 5.6 months, and median overall survival of just 12.3 months. Safety in lung 202 is consistent with our lyfaloosal experience to date across our clinical trials of multiple solid tumors. Encouragingly, the safety profile on Lung 202 improved using the updated reduced-dose lymphodepletion regimen. Efficacy, including durability, remains comparable and consistent in Lung 202 before and after the change to reduced-dose lymphodepletion. We will provide more details on Lung 202 as the study completes with potential presentations at medical meetings in 2027. Looking ahead, we are confident in our plans to submit a supplemental biologics license application, or SBLA, in 2027. We are completing enrollment in cohorts 1 and 2 with a target of approximately 80 patients for the SPLA. In parallel, we are advancing independent review committee assessments, FDA discussions, and other pre-submission activities, including preparation for a confirmatory trial. Alongside our latest Lung 202 update, we launched an innovative precision TIL strategy. We identified a biomarker-enriched subgroup of non-squamous, non-small cell lung cancer patients in Lung 202 demonstrated a remarkable 59.1% response rate. Nearly 6 in 10 patients showed a deep and durable response. These results are the foundation for Positility, a first-in-class, prospectively defined, biomarker-enriched cohort with registrational intent that we will pursue in addition to our initial SVLA in 2027 in non-squamous, non-small-cell lung cancer. Positility is targeting 80 patients and will begin enrollment this month. utilizing the existing Lung202 site footprint to speed enrollment as part of a planned transition. In 2027, we are also planning our OPTALISM trial to investigate this population in the frontline setting. Together, these biomarkers selected front and second-line settings representing U.S. opportunity about 10 times the size of advanced melanoma. At the ESMO Congress in late October, two oral presentations showcased the broader potential for Leflusol to demonstrate Doable Responses in Soft Tissue Sarcomas and Frontline Advanced Melanoma. Following one of the oral sessions at ESMO, this morning's press release included our most recent updates in soft tissue sarcoma. The confirmed ORR by RESIST-1-1 for lipolucel and refractory undifferentiated pleomorphic sarcoma, or UPS, and dedifferentiated liposarcoma, or DDLPS, has climbed to 55.6%, five of nine patients. Multiple durable responses have already been observed, including two ongoing more than a year from infusion. Safety in the sarcoma trial is consistent with our Lepalooza experience to date across our clinical trials of multiple solid tumors. These powerful results in heavily pre-treated patients are the basis for Saratoga, our registration trial that is actively enrolling to support tumor approvals for Lepalooza. After failing chemotherapy, second-line response rates are typically below 5%. Median survival is about nine to 10 months, and there are no approved immunotherapies. In recognition of this unmet need, as well as our initial results, the FDA granted fast track designation in both UPS and DDLPS. In addition, we have aligned with the agency on the design and a potential accelerated approval pathway based on the Saratoga trial with 40 patients expected in each cohort and SPLA submissions planned for 2028 or 2029. In our second oral session at ESMO, we focused on frontline advanced melanoma. where about half of patients do not achieve long-term benefit with today's standard combination checkpoint inhibitors. In our phase two cohort, frontline advanced melanoma, 62.5% of patients responded, including complete responses in 29.2% of patients where tumors disappeared completely and did not return. Median overall survival was not reached after more than four years of follow-up. Safety was consistent with the known safety profiles of one time , and . These results reinforce TILVANS 301, our Phase III trial enrolling in more than 80 sites and expanding design and support for the frontline approval and serve as the confirmatory trial for full U.S. approval of . In summary, IVANS is focused on growing revenue, expanding in the new indications and markets, broadening TIL therapy in the solid tumor indications, including biomarker-selected populations, and collectively represent tens of thousands of cancer patients for prognosis, and limited available options. I am also thrilled to welcome our new chief medical officer, Dr. Noah Berkowitz, to his first quarterly call at Iovance to discuss additional details about our pipeline. His valuable expertise in global drug development across cancer and blood disorders led to approvals for the CAR-T cell therapies of Beck Membrionzi, Watt, Bristol-Myers Squibb. As the first and only company in the world to take TILT therapy from concept to commercial treatment, We are forging ahead with tremendous momentum toward profitability and long-term value for patients and shareholders alike. Corleen Roche, our Chief Financial Officer, will now highlight our financial results.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API